A Phase I, Placebo Controlled, Randomized, Subject-And Investigator-Blind, Sponsor-Open, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05180999 In Healthy Adult Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2014
At a glance
- Drugs PF-5180999 (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Pfizer
- 21 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to withdrawn prior to recruitment.
- 08 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2014 to 1 Jan 2015.
- 10 Feb 2014 Planned End Date changed from 1 Jul 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.